Prognostic value of PD -L1 expression in patients with primary solid tumors

• DOI: 10.18632/oncotarget.23580
• Publication Date: 2017-12-22T08:18:17Z
• Authors: Xiao Xiang; Peng-Cheng Yu; Di Long; Xiao-Li Liao; Sen Zhang; Xue-Mei You; Jian-Hong Zhong; Le-Qun Li
• Keywords: Solid tumor

Programmed death-ligand 1 (PD-L1) is thought to play a critical role in immune escape by cancer, but whether PD-L1 expression can influence prognosis of patients with solid tumors controversial. Therefore, we meta-analyzed available data on correlates overall survival (OS) such patients. PubMed, EMBASE and other databases were systematically searched for cohort or case-control studies examining the possible correlation between OS tumors. was compared positive negative using scatter plots, subgroup analyses performed based tumor type patient characteristics. Data from 59 involving 20,004 meta-analyzed. The median percentage 30.1%. significantly lower PD-L1-positive than PD-L1-negative at year (P = 0.039), 3 years < 0.001) 5 0.001). risk ratios (and associated 95% confidence intervals) 2.02 (1.56-2.60) year, 1.57 (1.34-1.83) 1.43 (1.24-1.64) years. Similar results obtained ethnicity type. evidence suggests that negatively affects might serve as an efficient prognostic indicator may represent important new therapeutic target.